Abbott Laboratories (ABT) EBT Margin (2009 - 2026)

Abbott Laboratories has disclosed EBT Margin across 18 years of filings, most recently posting 12.98% for Q1 2026.

• EBT Margin for Q1 2026 came in at 12.98%, down 419.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 18.03% (up 66.0% YoY), and the FY2025 annual result was 19.1%, up 238.0% from the prior year.
• EBT Margin came in at 12.98% for Q1 2026 at Abbott Laboratories, down from 20.58% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 24.18% in Q1 2022 to a low of 12.98% in Q1 2026.
• The 5-year median for EBT Margin is 17.17% (2025), against an average of 17.49%.
• Across the five-year window, EBT Margin surged 771 bps in 2022 and slumped 815 bps in 2023, its largest moves.
• Abbott Laboratories' EBT Margin stood at 13.08% in 2022, then soared by 34 bps to 17.53% in 2023, then climbed by 6 bps to 18.5% in 2024, then advanced by 11 bps to 20.58% in 2025, then sank by 37 bps to 12.98% in 2026.
• The last three EBT Margin figures came in at 12.98% (Q1 2026), 20.58% (Q4 2025), and 19.17% (Q3 2025), per Business Quant data.